VTRS

EX-99.1

2 exhibit991-1q26earningsrel.htm

EX-99.1

Document

Viatris Reports First-Quarter 2026 Financial Results

•Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million

•Total Revenues Were Up 3% Operationally Compared to First Quarter 2025

•Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage

•Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in Japan

•Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026

•Reaffirms 2026 Financial Guidance [1]

PITTSBURGH – May 7, 2026 – Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results.

Executive Commentary

“We delivered a strong first quarter, reflecting disciplined execution across our global businesses,” said Scott A. Smith, CEO, Viatris. “Our performance reinforces the growth trajectory we outlined at our Investor Event in March. We saw continued momentum in key markets like Greater China and North America, progressed on launches and advanced our pipeline with multiple near-term catalysts. We expect to generate significant cash in 2026, providing flexibility to execute against our balanced capital allocation framework. Based on our strong start, we believe we are well positioned to deliver on our full-year guidance, and we remain focused on building a more durable, higher-quality growth profile for Viatris.”

[1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or U.S. GAAP diluted EPS (loss) or a quantitative reconciliation of its 2026 Adjusted EBITDA or Adjusted EPS guidance. U.S. GAAP net cash provided by operating activities for 2026 is estimated to be between $1.7 billion and $2.0 billion, with a midpoint of approximately $1.85 billion. 2026 financial guidance ranges as provided on February 26, 2026, and reaffirmed on May 7, 2026, exclude the impact of any transaction-related and restructuring-related costs (as defined below) and acquired IPR&D for unsigned deals as they cannot be reasonably forecasted. Please see “2026 Financial Guidance” and “Non-GAAP Financial Measures” for additional information.

First-Quarter Results

Three Months Ended

March 31,

(Unaudited; in millions, except %s and per share amounts) 20262025Reported Change Operational Change(1) (2)

Total Revenues $3,517.0 $3,254.3 8%3%

Total Net Sales$3,509.7 $3,243.2 8%3%

Developed Markets2,020.8 1,891.7 7%1%

Emerging Markets535.4 519.9 3%—%

JANZ273.4 276.1 (1)%(2)%

Greater China680.1 555.5 22%18%

Net Sales by Product Category

Brands$2,332.5 $2,116.9 10%4%

Generics 1,177.2 1,126.3 5%1%

U.S. GAAP Gross Profit$1,157.2 $1,161.2 —%

U.S. GAAP Gross Margin32.9 %35.7 %

Adjusted Gross Profit (2) $1,970.3 $1,819.6 8%

Adjusted Gross Margin (2) 56.0 %55.9 %

U.S. GAAP Net Earnings (Loss) (3)

$176.4 $(3,042.0)NM

U.S. GAAP Earnings (Loss) Per Share (3)

$0.15 $(2.55)NM

Adjusted Net Earnings (2) $694.1 $600.3 16%

Adjusted EPS (2) $0.59 $0.50 18%14%

EBITDA (2)

$548.9 $(2,316.8)NM

Adjusted EBITDA (2) $1,049.5 $923.5 14%10%

U.S. GAAP Net Cash Provided by Operating Activities $388.3 $535.5 (27)%

Capital Expenditures 39.9 42.6 (6)%

Free Cash Flow (2)(4) $348.4 $492.9 (29)%

(1)     See “Certain Key Terms and Presentation Matters” in this release for more information.

(2)    Non-GAAP financial measures. See “Non-GAAP Financial Measures” for additional information.

(3)    For the three months ended March 31, 2025, includes the previously disclosed goodwill impairment charge of $2.9 billion as a result of the interim goodwill impairment test performed as of March 31, 2025.

(4)    Excluding the impact of transaction-related and restructuring-related costs of $111 million, free cash flow for the three months ended March 31, 2026, was $459 million. Excluding the impact of transaction-related costs and taxes primarily related to the divestitures of $43 million, free cash flow for the three months ended March 31, 2025, was $535 million.

Financial Highlights for the First Quarter of 2026

•Total revenues were $3.5 billion, up 8% on a reported basis and up 3% on an operational basis compared to first-quarter 2025 results, primarily driven by strong growth in Greater China.

•Brands net sales reflect accelerated growth in Greater China and continued strength in Emerging Markets.

•Generics net sales reflect contributions from new product launches, in addition to growth of certain products in North America, partially offset by supply constraints in our ARV business within Emerging Markets.

2

•The Company generated approximately $71 million in new product revenues in the quarter and continues to expect to deliver approximately $450 million to $550 million in new product revenues in 2026.

•U.S. GAAP net earnings were $176 million compare

vtrs-20260223false000179204400017920442026-02-232026-02-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026

VIATRIS INC.

(Exact name of registrant as specified in its charter)

Delaware001-3969583-4364296 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317 (Address of Principal Executive Offices)

Registrant's telephone number, including area code: (724) 514-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareVTRSThe NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Item 2.02 Results of Operations and Financial Condition. On February 26, 2026, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended December 31, 2025 and announcing 2026 guidance. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 2.05 Costs Associated with Exit or Disposal Activities. In 2025, Viatris initiated an enterprise-wide strategic review (“EWSR”) to enable the Company to build a more focused, efficient and future-ready organization and position the Company for sustained growth beginning in 2026. On February 26, 2026, the Company announced the results of its EWSR, and as a part of the review, committed to and began implementation of certain restructuring activities. These restructuring activities are expected to optimize the Company’s commercial capabilities, enabling functions, R&D, medical affairs and regulatory activities, and sourcing, manufacturing and supply chain activities, including inventory optimization. As a result, the Company expects a global workforce reduction of up to approximately 10%. The Company anticipates that these restructuring activities, as well as associated costs and savings, will be completed primarily over the next three years.

The Company expects to record charges for costs associated with the restructuring activities of the EWSR. For the committed restructuring activities, the Company expects to incur total pre-tax charges ranging between $700 million and $850 million. Such charges are expected to include between $50 million and $100 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of between $650 million and $750 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations, vendor consolidations, product transfer costs and network related simplification and modernization costs. In addition, management believes the potential savings related to these committed restructuring activities will be between $600 million and $700 million once fully implemented, with most of these savings expected to improve operating cash flow.

As permitted by Item 2.05 of Form 8-K, the Company will file an amendment to this report if charges and future cash costs differ materially from current estimates.

Item 8.01

vtrs-20251106false000179204400017920442025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025

VIATRIS INC.

(Exact name of registrant as specified in its charter)

Delaware001-3969583-4364296 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317 (Address of Principal Executive Offices)

Registrant's telephone number, including area code: (724) 514-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareVTRSThe NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m. ET to review the Company's financial results for the period ended September 30, 2025.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.  Description 99.1 Press release announcing the Company's financial results for the third quarter of 2025, dated November 6, 2025.

104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIATRIS INC.

Date: November 6, 2025By:/s/ THEODORA MISTRAS Theodora Mistras Chief Financial Officer